← Back to Search

Diagnostic Scans for Breast Cancer

Q: Are there still available positions for participants in this research?

<p>As per clinicaltrials.gov, this medical trial is currently gathering participants and was initially posted on March 1st 2023 with the latest update made February 21st 2023.</p>

Q: What is the aggregate figure of participants engaged in this research?

<p>Verified. Clinicaltrials.gov indicates that this medical trial, which was initially made public on March 1st 2023, is currently enrolling patients. A total of twenty participants are sought from one medical facility.</p>

Phase < 1

Recruiting

Led By Rachel Hitt, MD

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up calculated once all imaging is complete [anticipated 1.5 years]

Awards & highlights

Study Summary

This trial will compare two scans (CE-DBT & CE-MRI) to see which is better at finding breast lesions in patients.

Who is the study for?

This trial is for women aged 18 or older with suspected breast lesions (BIRADS 4+), who have had or will have a conventional breast MRI at UNC Hospitals within a three-month window around the research scan. Participants must be able to consent in writing and not be pregnant, as confirmed by tests or patient history.Check my eligibility

What is being tested?

The study aims to compare radiologist confidence when evaluating known breast lesions using two imaging techniques: contrast enhanced digital breast tomosynthesis (CE-DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI).See study design

What are the potential side effects?

Potential side effects may include allergic reactions to the iodinated contrast agent used in CE-DBT, such as skin rashes or more severe responses that could require medication like antihistamines or steroids.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ calculated once all imaging is complete [anticipated 1.5 years]

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~calculated once all imaging is complete [anticipated 1.5 years]

This trial's timeline: 3 weeks for screening, Varies for treatment, and calculated once all imaging is complete [anticipated 1.5 years] for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reader confidence in identifying lesions on CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units)

Secondary outcome measures

Contrast enhancement curves of CE-DBT compared to conventional MRI (arbitrary units)

Diagnostic accuracy of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units)

Positivity predictive value of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units)

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Contrast-enhanced digital breast tomosynthesis (CE-DBT)Experimental Treatment1 Intervention

Participants with known breast lesions will be imaged using contrast-enhanced digital breast tomosynthesis (CE-DBT) with Iohexol 350 mg I/mL.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,313 Total Patients Enrolled

51 Trials studying Breast Cancer

27,966 Patients Enrolled for Breast Cancer

Rachel Hitt, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Media Library

Contrast-enhanced digital breast tomosynthesis (CE-DBT) Clinical Trial Eligibility Overview. Trial Name: NCT05754749 — Phase < 1

Breast Cancer Research Study Groups: Contrast-enhanced digital breast tomosynthesis (CE-DBT)

Breast Cancer Clinical Trial 2023: Contrast-enhanced digital breast tomosynthesis (CE-DBT) Highlights & Side Effects. Trial Name: NCT05754749 — Phase < 1

Contrast-enhanced digital breast tomosynthesis (CE-DBT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05754749 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still available positions for participants in this research?

"As per clinicaltrials.gov, this medical trial is currently gathering participants and was initially posted on March 1st 2023 with the latest update made February 21st 2023."

Answered by AI

What is the aggregate figure of participants engaged in this research?

"Verified. Clinicaltrials.gov indicates that this medical trial, which was initially made public on March 1st 2023, is currently enrolling patients. A total of twenty participants are sought from one medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

2023. "Comparison of CE-DBT and MRI in Patients With Known Breast Lesions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05754749.